Association between serum C-reactive protein (CRP) and Omicron variant COVID-19 pneumonia in cancer patients: A multicenter cross-sectional study at the end of 2022 in China.

Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE

Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins

C-Reactive Protein*/chemistry ; COVID-19*/diagnosis ; COVID-19*/metabolism ; Neoplasms*/complications ; Neoplasms*/epidemiology; Humans ; China/epidemiology ; Cross-Sectional Studies ; Prognosis ; Retrospective Studies ; SARS-CoV-2/metabolism

Cancer patients with COVID-19 have a higher infection rate and mortality rate than non-cancer patients. However, there are few studies on the correlation between the serum C-reactive protein (CRP) and cancer patients with COVID-19. This study aims to investigate the association between serum CRP and the incidence of COVID-19 pneumonia in cancer patients at the end of 2022 in China. This cross-sectional study with a retrospective cohort between December 2022 and February 2023 assessed cancer patients complicated with COVID-19 infection in 2 Chinese institutions. Logistic regression analyses were used to compute Odds ratio (OR) and 95%CIs for the association between serum CRP and the incidence of COVID-19 pneumonia in cancer patients. A total of 213 cancer patients with COVID-19 were enrolled. Eighty-six patients (40.4%) developed COVID-19 pneumonia, among which 23 patients (10.8%) progressed to severe cases. Univariate Logistic regression showed that high CRP levels were found to be an unfavorable predictor of COVID-19 outcomes (OR = 17.9, 95%CI: 7.3, 43.6; P < .001). In the multivariate analysis, high CRP levels were associated with a higher incidence rate of COVID-19 pneumonia (OR = 9.8, 95%CI: 2.2, 43.8; P = .003). In the multivariate logistic regression model and smooth curve fitting, we found a correlation between CRP and COVID-19 pneumonia. The serum CRP was associated with the incidence of Omicron variant COVID- 19 pneumonia in cancer patients. Hence, cancer patients with high CRP level maybe need for timely computer tomography examination and more aggressive treatment.
Competing Interests: The authors have no conflicts of interest to disclose.
(Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)

Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022;399:437–46.
Chen J, Wang R, Gilby NB, et al. Omicron variant (B11529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model. 2022;62:412–22.
Cheung PHH, Chan CP, Jin DY. Lessons learned from the fifth wave of COVID-19 in Hong Kong in early 2022. Emerg Microbes Infect. 2022;11:1072–8.
Zhang X, Zhang W, Chen S. Shanghai’s life-saving efforts against the current omicron wave of the COVID-19 pandemic. Lancet. 2022;399:2011–2.
Chakraborty C, Bhattacharya M, Sharma AR, et al. Recombinant SARS-CoV-2 variants XD, XE, and XF: The emergence of recombinant variants requires an urgent call for research – Correspondence. Int J Surg. 2022;102.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prevention and Treatment of Cancer-Related Infections.Version 3.2022. J Natl Compr Cancer Netw. 2022.
Molins B, Figueras-Roca M, Valero O, et al. C-reactive protein isoforms as prognostic markers of COVID-19 severity. Front Immunol. 2023;13:1105343.
Cao B, Jing X, Liu Y, et al. Comparison of laboratory parameters in mild vs severe cases and died vs survived patients with COVID-19: systematic review and meta-analysis. J Thorac Dis. 2022;14:1478–87.
Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med 2021;26:107–8.
Khedar RS, Gupta R, Sharma K, et al. Biomarkers and outcomes in hospitalised patients with COVID-19: a prospective registry. BMJ Open. 2022;12:e067430.
Gorog DA, Storey RF, Gurbel PA, et al. Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nat Rev Cardiol. 2022;19:475–95.
Liu C, Wang K, Li L, et al. Severity of COVID-19 in Cancer patients versus patients without Cancer: a Propensity Score Matching Analysis. J Cancer. 2021;12:3558–65.
Zhou J, Lakhani I, Chou O, et al. Clinical characteristics, risk factors and outcomes of cancer patients with COVID-19: a population-based study. Cancer Med. 2023;12:287–96.
Yang S, Zhao H, Cui R, et al. Comparison of clinical outcomes and risk factors for COVID-19 infection in cancer patients without anticancer treatment and noncancer patients. Front Public Health. 2022;10:925519.
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7.
von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Int J Surg. 2014;12.
Ulloa AC, Buchan SA, Daneman N, et al. Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada. JAMA. 2022;327:1286–8.
Sheikh A, Kerr S, Woolhouse M, et al. Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. Lancet Infect Dis. 2022;22.
Strasser ZH, Greifer N, Hadavand A, et al. Estimates of SARS-CoV-2 Omicron BA2 Subvariant Severity in New England. JAMA Netw Open. 2022;5:e2238354.
Gabay C, Kushner I. Acute-Phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–54.
Smilowitz NR, Kunichoff D, Garshick M, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021;42:2270–9.
Luo W, Zhang JW, Zhang W, et al. Circulating levels of IL-2, IL-4, TNF-α, IFN-γ, and C-reactive protein are not associated with severity of COVID-19 symptoms. J Med Virol. 2021;93:89–91.
Wang D, Li R, Wang J, et al. Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study. BMC Infect Dis. 2020;20.
Liu F, Li L, Da XM, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127.
Zeng F, Huang Y, Guo Y, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. 2020;96:467–74.
Luo H, yan YC, wei LS, et al. Characteristics of coagulation alteration in patients with COVID-19. Ann Hematol. 2021;100.
Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;92.
Passaro A, Bestvina C, Velez Velez M, et al. Severity of COVID-19 in patients with lung cancer: evidence and challenges. J ImmunoTher Cancer. 2021;9.
Zhou Y, Yang Q, Ye J, et al. Clinical features and death risk factors in COVID-19 patients with cancer: a retrospective study. BMC Infect Dis. 2021;21.
Smith M, Lara OD, O’Cearbhaill R, et al. Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection. Gynecol Oncol. 2020;159:618–22.
Beebe-Dimmer JL, Lusk C, Ruterbusch JJ, et al. The impact of the COVID-19 pandemic on African American cancer survivors living in metropolitan Detroit. J Clin Oncol. 2021;39(15_suppl.
Belluomini L, Caldart A, Avancini A, et al. Infections and immunotherapy in lung cancer: a bad relationship? Int J Mol Sci . 2021;22.
Khorasanizadeh F, Kaviani S, Salamroudi S, et al. Role of chest CT scan in patients with preexisting cancer and COVID-19 pneumonia. BMC Med Imaging. 2023;23:27.
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395.
Russell B, Moss CL, Shah V, et al. Risk of COVID-19 death in cancer patients: an analysis from Guy’s Cancer Centre and King’s College Hospital in London. Br J Cancer. 2021;125:939–47.
Iaccarino G, Grassi G, Borghi C, et al. Age and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS study of the Italian Society of Hypertension. Hypertension. 2020;76:366–72.
Sonaglioni A, Lombardo M, Albini A, et al. Charlson comorbidity index, neutrophil-to-lymphocyte ratio and undertreatment with renin-angiotensin-aldosterone system inhibitors predict in-hospital mortality of hospitalized COVID-19 patients during the omicron dominant period. Front Immunol. 2022;13:958418.
Shrestha LB, Foster C, Rawlinson W, et al. Evolution of the SARS-CoV-2 omicron variants BA1 to BA5: implications for immune escape and transmission. Rev Med Virol. 2022;32.

9007-41-4 (C-Reactive Protein)

SARS-CoV-2 variants

Date Created: 20240112 Date Completed: 20240206 Latest Revision: 20240227

20240227

PMC10783274

10.1097/MD.0000000000036965

38215120